H.C. Wainwright: Roche’s “Disappointing” persevERA Failure Is Not a Full Read-Through for Olema

H.C. Wainwright calls Roche’s persevERA trial disappointing but says it’s not a full readthrough for Olema Oncology. Different CDK4/6 inhibitor (ribociclib) may favor palazestrant in OPERA-02.